leisure time -WSS

leisure time

author：knowledge 2025-09-27 19:50:18 - browse：4

Adam's take main illustration — Molly Ferguson/STAT

Hello! Some takes and thoughts on Gilead’s Trodelvy troubles, Elevation Oncology’s surprising rise, and Kura Oncology’s “wall-crossing” stock sale.

Gilead needs Arcellx more than ever

The clinical trial setback for Trodelvy in non-small cell lung cancer reported by Gilead Sciences on Monday was another dose of bad news for the company’s oncology business. Strategically, does it make sense for Gilead to invest even more in antibody-drug conjugates like Trodelvy, where its lackluster profile and increased competition overall makes winning seem unlikely? Or, should Gilead double down on its Kite division and CAR-T cell therapy — the type of cancer treatments where it truly excels?

If the answers to those questions are no and yes (I lean that way), then Gilead’s current partnership with Arcellx, which is developing a BCMA-targeted CAR-T therapy for multiple myeloma, becomes a lot more important.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： HPV cancer vaccine study demonstrates efficacy

WSS

Readout LOUD Podcast: Legal insider trading, booming biotech stocks

Will General Catalyst be the first of many hospital takeovers?

Study: New antibiotic targets gonorrhea as well as last existing drug

Victims of gun violence feel impacts long after bullet wound

Ambulance rides for just $100? Advisers want major billing fixes

Change Healthcare cyberattack outage could last weeks

hotspot

leisure time

Gilead needs Arcellx more than ever

hotspot

Malaria cases in Florida and Texas: Here’s what you need to know

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

Continuity nursing helped my family in our darkest PICU moments

The new shift in health care is toward less care

As demand for Covid shots wanes, Moderna seeks its next success

Sanofi CEO defends move to abandon profit guidance, boost research

The cancer drug shortage isn’t new — and neither are the solutions

Covid isolation guidance eased by the CDC

Walensky prepares to leave CDC — and Congress — behind

RaDonda Vaught to speak at CommonSpirit event on patient safety

explore

A clever new way to fix Medicaid and graduate medical education

How to fix the rural physician shortage in the U.S.

Don't let 'shelved assets' gather dust. Make them into new lifesaving drugs

The new shift in health care is toward less care

AstraZeneca loses challenge to Medicare drug price negotiation

RaDonda Vaught to speak at CommonSpirit event on patient safety

focus

focus

hotspot

explore